Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions

International Journal of COPD

Volumn 2, Issue 4, 2007, Pages 599-607

  Kamin, Wolfgang ^a   Schwabe, Astrid ^b   Krämer, Irene ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Albuterol; Compatibility; COPD; Fluticasone; HPLC; Inhalation; Ipratropium; Nebulizer

Indexed keywords

FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; SALBUTAMOL; SALBUTAMOL SULFATE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CONTAMINATION; DRUG INCOMPATIBILITY; DRUG MIXTURE; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIGHT EXPOSURE; MEDICAL NEBULIZER; OSMOLARITY; PH MEASUREMENT; PHYSICAL CHEMISTRY; RADIATION DETECTION; ROOM TEMPERATURE; SUSPENSION;

ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; DRUG INCOMPATIBILITY; DRUG STORAGE; GERMANY; HUMANS; IPRATROPIUM; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 38049121633     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Balmes JR, Fine JM, Christian D, et al. 1988. Acidity potentiates bronchoconstriction induced by hypoosmolar aerosols. Am Rev Respir Dis, 138:35-9.
2. Beasley R, Rafferty P, Holgate ST. 1988. Adverse reaction to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol, 25:283-8.
3. Boe J, Dennis JH, O'Driscoll BR, et al. 2001. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J, 18:228-42.
4. Boulet LP, Legris C, Thibault L, et al. 1987. Comparative bronchial responses to hyperosmolar saline and methacholine in asthma. Thorax, 42:953-8.
5. Clay MM, Pavia D, Newman SP, et al. 1983. Assessment of jet nebulizers for lung aerosol therapy. Lancet, 2:592-94.
6. Elwood RK, Hogg JC, Paré PD. 1982. Airway response to osmolar challenge in asthma (abstract). Am Rev Respir Dis, 125:61.
7. Eschenbacher WL, Boushey HA, Sheppard D. 1984. Alteration in Osmolality of inhaled aerosols cause bronchoconstriction and cough, but absence of a permanent anion causes cough alone. Am Rev Respir Dis, 129:211-15.
8. Fachinformation. 2004a. Flutide® "ready to go" 0.5 mg/2.0 ml, Suspension, Flutide® forte "ready to go" 2.0 mg/2 ml, Suspension, 08/2004 GlaxoSmithKlimn GmbH and Co. KG, München.
9. Fachinformation. 2004b. Sultanol® "ready to go", Sultanol® forte "ready to go", Sultanol® inhalation solution, 04/2004 GlaxoSmithKline GmbH and Co. KG, München.
10. Fachinformation. 2005. Atrovent® LS, 04/2005 Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim am Rhein.
11. Fine JM, Gordon T, Thompson JE, et al. 1987. The role of fitratable acidity in acid aerosol-induced bronchoconstriction. Am Rev Respir Dis, 135:826-30.
12. Gronberg S, Magnusson P, Bladh N. 2001. Chemical Compatibility of Budesonide Inhalation Suspension (Pulmicort™) with other nebulization products. Am J Respir Crit Care Med, 163:A588.
13. Jacobson GA, Peterson GM. 1995. Stability of ipratropium. bromide and salbutamol nebuliser admixtures. Int J Pharm Pract, 3:169-73.
14. Kamin W, Schwabe A, Krämer I. 2006. Inhalation solutions-which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros, 5(4):205-13.
15. Mann JS, Howarth PH, Holgate ST. 1984. Bronchoconstriction induced by ipratropium. bromide in asthma: relation to hypotonicity. BMJ, 289:469.
16. McKenzie J, Gronberg S, Cruz Rivera M, et al. 2002. Budesonide inhalation suspension can be nebulized with solutions containing albuterol sulphate [poster]. Chest, 122 (Suppl): 183S.
17. McKenzie JE, Cruz-Rivera M. 2004. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother, 38:967-72.
18. Nagtegaal JE, De Jong A, De Waard WJ, et al. 1997. Formulation and shelf life of two solutions for inhalation. Ziekenhuisfarmacie, 13:23-9.
19. O'Callaghan C, Milner AD, Swarbrick A. 1989. Paradoxical broncho-constriction in wheezing infants after nebulised preservative free isoosmolar ipratopium bromide. BMJ, 299:1433-34.
20. Pharmacopoeia Europea. 2005. 5th Ed. Deutscher Apotheker Verlag, Stuttgart, Govi-Verlag-Pharmazeutischer Verlag, Eschborn.
21. Schoeffel RG, Anderson SD, Altounyan RE. 1981. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. BMJ, 283:1285-87.
22. Schwabe A, Krämer I, Kamin W 2005. Physico-chemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions. DPhG-Jahrestagung, Mainz, 05.-08.10.2005; Abstract ISBN 3-00-016844-3.
23. Smaldone GC, McKenzie J, Cruz Rivera M. 2000a. Effect of nebulizer volume on drug delivery: budesonide inhalation suspension. Am J Respir Crit Care Med, 161:A36.
24. Smaldone GC, McKenzie J, Cruz Rivera M, et al. 2000b. Budesonide inhalation suspension is chemically compatible with other nebulizing formulations [abstract]. Chest, 118:98S.
25. van den Bemt PMLA, de Bijl G, Langen MCJ, et al. 1997. Validation of two methods for the analysis of salbutamol/ipratropium inhalation fluid. Ziekenhuisfarmacie, 13:92-5.